Background and purpose: This study investigates the effect of pravastatin on systolicblood pressure, cardiovascular remodeling and impaired endothelial function induced as earlysigns of cardiovascular disease in fludrocortisone-salt induced hypertensive rats.Methods: The study of protective and therapeutic effects of pravastatin at a dose of20mg/kg/day/orally was carried out on 32 albino male rats (150- 200 g) randomly assignedinto four groups: Normal group (distilled water for 8 weeks), Hypertensive group(fludrocortisones 250μ/kg/day/orally +1% salt for 8 weeks), pravastatin pretreated group(pravastatin for 8 weeks+ fludrocortisone+1% salt from4th week to 8th week) and pravastatintreated group (fludrocortisone+1% salt for 8 weeks+ pravastatin from4th week to 8th week).The effect of protection was assessed by systolic blood pressure measurement,echocardiographic data (LVEDD, LVESD, EF and FS %), vascular response of aorta tophenylephrine and acetylcholine, histomorphometric changes of aorta and biochemicalmeasurements (MDA, superoxide anion and nitrite in urine).Results: Pravastatin produced significantly hypotensive effect in pretreated (125.23±4.54mmHg) and treated (119.53±3.2 mmHg) groups compared to hypertensive group (174±1.08mmHg) at the end of the study, and LVH was significantly reduced by pravastatin in bothgroups. There was significant (p<0.05) increase in Phenylephrine contraction in hypertensivegroup compared to pretreated and treated group and there was high significant (p<0.05)increase in relaxation of aorta to Ach in pretreated and treated group compared to hypertensivegroup. Superoxide anions, MDA were reduced and urinary nitrite was elevated by pravastatintreatment. Finally pravastatin prevented aortic wall thickening after treatment.Conclusion: Pravastatin, independent of its lipid-lowering properties, could be a usefultherapeutic agent to prevent the development of cardiovascular disorders in prehypertensive and hypertensive states.